B. Riley analyst Mayank Mamtani lowered the firm’s price target on Vaxart (VXRT) to $2 from $2.50 and keeps a Buy rating on the shares. The Q4 ...

Lisa Ricciardi; President, Chief Executive Officer, Director; Cognition Therapeutics Inc. John Doyle; Chief Fi ...

Detailed price information for Trevi Therapeutics Inc (TRVI-Q) from The Globe and Mail including charting and trades.

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $11 and keeps a Buy rating on the ...

Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter 2024 financial results call. Please note that this call is being recorded. (Operator Instructions) I'd now like to hand the call over ...

This analyst has an accuracy rate of 60%. B. Riley Securities analyst Mayank Mamtani reiterated a Buy rating with a price target of $50 on Aug. 29, 2024. This analyst has an accuracy rate of 72%.

B. Riley Securities Managing Director & Group Head of Healthcare Research Mayank Mamtani joins Market Domination to break down the deal. The co-exclusive licensing agreement between the two ...

4 analysts have expressed a variety of opinions on Nektar Therapeutics NKTR over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a ...

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the company announced a “long-awaited” manufacturing agreement with ...

Emily Bodnar: Okay, great. Thank you. Operator: [Operator Instructions] And our next question comes from the line of Mayank Mamtani with B. Riley Securities. Please go ahead. Mayank Mamtani ...

India's fastest bowler Mayank Yadav might miss the early matches of the upcoming Indian Premier League for Lucknow Super Giants. He is not fully fit yet and is currently undergoing recovery at BCCI's ...